Pembrolizumab-ipilimumab combo is highly active in advanced melanoma

CHICAGO – The combination of pembrolizumab, an antibody to the human cell surface receptor programmed death-1 (PD-1), and ipilimumab, an antibody to the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), is highly active against advanced melanoma and has acceptable safety,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news